FRLN News and Press, Freeline Therapeutics Holdings plc From 02/03/22

Freeline Therapeutics (NASDAQ:FRLN) granted three newly hired employees non-statutory options to purchase 66.4K of its shares. Each of the options has an exercise price of $1.18/share. The options have a maximum 10-year term and vest over a 4-year service period, with 25% of the award ve...

LONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene ...

LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people with inherited systemic debilitating...

These Penny Stocks Climbed During Premarket, Here’s Why One of the best ways to stay ahead with penny stocks is to find the largest premarket gainers. While this is in no way the only strategy to use when trading penny stocks , it can be a major asset. Typically, premarket ga...

FLT201 is the first AAV gene therapy program to enter the clinic for Gaucher disease Type 1 FLT201 Phase 1/2 trial for Gaucher disease Type 1 on track for patient dosing in the first half of 2022 LONDON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Freeline T...

LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today...

Promising execution in the clinic with programs in hemophilia B, Fabry disease and Gaucher disease; potential to deliver transformative therapies driven by Freeline’s differentiated platform Data anticipated across all programs by mid-2022 FLT180a B-LIEVE trial fo...

B-AMAZE long-term follow up data demonstrate sustained FIX expression up to 3.5 years; potential for expression levels in the normal range with relatively low vector doses B-LIEVE trial to confirm dose and immune management for planned Phase 3 pivotal trial launch...

LONDON, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic ...

LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic ...